CA2517291A1 - Ortho-substituted aryl and heteroaryl tie-2 modulators and methods of use - Google Patents
Ortho-substituted aryl and heteroaryl tie-2 modulators and methods of use Download PDFInfo
- Publication number
- CA2517291A1 CA2517291A1 CA002517291A CA2517291A CA2517291A1 CA 2517291 A1 CA2517291 A1 CA 2517291A1 CA 002517291 A CA002517291 A CA 002517291A CA 2517291 A CA2517291 A CA 2517291A CA 2517291 A1 CA2517291 A1 CA 2517291A1
- Authority
- CA
- Canada
- Prior art keywords
- optionally substituted
- compound according
- co2r3
- substituted lower
- ring system
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases, particularly Tie-2. Methods of using the compounds and pharmaceutical compositions thereof to treat kinase-dependent diseases and conditions are also an aspect of the invention.
Claims (50)
1. A compound for modulating kinase activity of Formula I, or a pharmaceutically acceptable salt, hydrate, or prodrug thereof, wherein, Ar is a five- to six-membered aromatic ring system containing between one and three heteroatoms, said five- to six-membered aromatic ring system substituted with -X and -Y-L-Z, in an ortho relationship to each other, and said five- to six-membered aromatic ring system optionally substituted with up to four R1;
each R1 is independently selected from -H, halogen, -CN, -NO2, -OR3, -N(R3)R3, -s(O)O-2R3' -SO2N(R3)R3, -CO2R3, -C(O)N(R3)R3, -N(R3)SO2R3, -N(R3)C(O)R3, -N(R3)CO2R3, -C(O)R3, -OC(O)R3, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl;
optionally two of R1, together with the atoms to which they are attached, form a first ring system fused with Ar, said first ring system substituted with zero to three additional of R1;
X is selected from the following six formulae:
wherein, W is selected from -C(R2)(R2)-, -N(R4)-, -S(O)0-2-, and -O-;
n = 1 or 2;
p=0 or 1;
q is 1 to 3;
M is -OR3 or -N(R3)R4;
each R2 is independently selected from -H, halogen, oxo, -CN, -NH2, -NO2, -OR3, -N(R3)R3, -N(R3)R5, -S(O)0-2R3, -SO2N(R3)R3, -CO2R3, -C(O)N(R3)R3, -N(R3)SO2R3, -N(R3)C(O)R3, -N(R3)CO2R3, -N(R3)C(O)N(R3)R3, -C(O)R3, -OC(O)R3, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl;
two of R2, together with the atoms to which they are attached, can form an optionally substituted three- to seven-membered ring system;
each R3 is independently selected from -H, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; or two of R3, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl ring, said optionally substituted five- to seven-membered heterocyclyl ring optionally containing at least one additional heteroatom selected from N, O, S, and P;
each R4 is independently selected from R3, -SO2R3, -SO2N(R3)R3, -CO2R3, -C(O)N(R3)R3, and -C(O)R3;
Y is selected from -CH2-, -O-, -S(O)0-2-, -N(R3)-, and absent;
L is selected from -(CH2)1-3-, -(CH2)1-3N(R3)-, -(CH2)1-3O-, -(CH2)1-3S(O)0-2-and absent;
each of the aforementioned methylenes optionally substituted;
Z is a five- to seven-membered ring system or -R3, said five- to seven-membered ring system optionally substituted with zero to four of R5; and R5 is selected from -H, halogen, -CN, oxo, -NO2, -OR3, -N(R3)R4, -S(O)0-2R3, -SO2N(R3)R3, -CO2R3, -C(O)N(R3)R, -N(R3)SO2R3, -N(R3)C(O)R3, -N(R3)CO2R3, -C(O)R3, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; and optionally two of R5, together with the atoms to which they are attached, form a second ring system fused with said five- to seven-membered ring system, said second ring system substituted with zero to four of R5.
each R1 is independently selected from -H, halogen, -CN, -NO2, -OR3, -N(R3)R3, -s(O)O-2R3' -SO2N(R3)R3, -CO2R3, -C(O)N(R3)R3, -N(R3)SO2R3, -N(R3)C(O)R3, -N(R3)CO2R3, -C(O)R3, -OC(O)R3, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl;
optionally two of R1, together with the atoms to which they are attached, form a first ring system fused with Ar, said first ring system substituted with zero to three additional of R1;
X is selected from the following six formulae:
wherein, W is selected from -C(R2)(R2)-, -N(R4)-, -S(O)0-2-, and -O-;
n = 1 or 2;
p=0 or 1;
q is 1 to 3;
M is -OR3 or -N(R3)R4;
each R2 is independently selected from -H, halogen, oxo, -CN, -NH2, -NO2, -OR3, -N(R3)R3, -N(R3)R5, -S(O)0-2R3, -SO2N(R3)R3, -CO2R3, -C(O)N(R3)R3, -N(R3)SO2R3, -N(R3)C(O)R3, -N(R3)CO2R3, -N(R3)C(O)N(R3)R3, -C(O)R3, -OC(O)R3, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl;
two of R2, together with the atoms to which they are attached, can form an optionally substituted three- to seven-membered ring system;
each R3 is independently selected from -H, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; or two of R3, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl ring, said optionally substituted five- to seven-membered heterocyclyl ring optionally containing at least one additional heteroatom selected from N, O, S, and P;
each R4 is independently selected from R3, -SO2R3, -SO2N(R3)R3, -CO2R3, -C(O)N(R3)R3, and -C(O)R3;
Y is selected from -CH2-, -O-, -S(O)0-2-, -N(R3)-, and absent;
L is selected from -(CH2)1-3-, -(CH2)1-3N(R3)-, -(CH2)1-3O-, -(CH2)1-3S(O)0-2-and absent;
each of the aforementioned methylenes optionally substituted;
Z is a five- to seven-membered ring system or -R3, said five- to seven-membered ring system optionally substituted with zero to four of R5; and R5 is selected from -H, halogen, -CN, oxo, -NO2, -OR3, -N(R3)R4, -S(O)0-2R3, -SO2N(R3)R3, -CO2R3, -C(O)N(R3)R, -N(R3)SO2R3, -N(R3)C(O)R3, -N(R3)CO2R3, -C(O)R3, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; and optionally two of R5, together with the atoms to which they are attached, form a second ring system fused with said five- to seven-membered ring system, said second ring system substituted with zero to four of R5.
2. The compound according to claim 1, of formula II, wherein, A and E are each independently N or -C(R1)-; and G is selected from -S(O)0-2-, and -C(R1)=C(R1)-.
3. The compound according to claim 2, wherein Ar is selected from the following formulae.
4. The compound according to claim 3, wherein -Y-L-Z is selected from the following formulae, wherein g is zero to two; D is selected from -C(R5)(R5)-, -O-, -S(O)0-2-, and -N(R4)-; Q is =N- or -C(R5)-, T is selected from absent, -N(R3)-, -S- and -O-; and each methylene between Y and T is optionally substituted; provided that when both Y and T are heteroatoms then g must be two.
5. The compound according to claim 4, wherein Y is -O- or optionally substituted -CH2-.
6. The compound according to claim 5, wherein X is selected from the following formulae.
7. The compound according to claim 6, wherein R4a is selected from -SO2R3, -SO2N(R3)R4, -CO2R3, -C(O)N(R3)R4, and -C(O)R3.
8. The compound according to claim 7, wherein each R2 is independently selected from -H or optionally substituted lower alkyl.
9. The compound according to claim 8, wherein each R2 is independently selected from -H, haloalkyl, -C1-6alkyl-N(R3)R3, -C1-6alkyl-OR3, -C1-6alkyl-CO2R3, and -C1-6alkyl-C(O)N(R3)R3.
10. The compound according to claim 9, wherein R4a is -C(O)N(R3)R3 or-C(O)R3.
11. The compound according to claim 10, wherein -Y-L-Z is selected from the following formulae, wherein Y, T, and g are as described above.
12. The compound according to claim 11, wherein g is one or two.
13. The compound according to claim 12, wherein each R5 is independently selected from -H, halogen, -CN, -NH2, -NO2, -OR3, -N(R3)R4, -S(O)0-2R3, -SO2N(R3)R3, -CO2R3, -C(O)N(R3)R3, -N(R3)SO2R3, -N(R3)C(O)R3, -N(R3)CO2R3, -C(O)R3, and optionally substituted lower alkyl.
14. The compound according to claim 13, wherein -Y-L-Z is selected from the following formulae.
15. The compound according to claim 14, having formula III, wherein J is N or CH, and B is =N- or =C(R5)-.
16. The compound according to claim 15, wherein R3a is selected from optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl.
17. The compound according to claim 16, wherein R3a is selected from optionally substituted aryl and optionally substituted heteroaryl.
18. The compound according to claim 17, wherein R3a is optionally substituted phenyl.
19. The compound according to claim 18, wherein said optionally substituted phenyl is substituted with at least one of halogen, -CN, -CF3, -NH2, -NO2, -OR3, -N(R3)R3, -S(O)0-2R3, -SO2N(R3)R3, -CO2R3, -C(O)N(R3)R3, -N(R3)SO2R3, -N(R3)C(O)R3, -N(R3)CO2R3, -C(O)R3, optionally substituted lower alkyl, and optionally substituted aryl.
20. The compound according to claim 19, wherein said optionally substituted phenyl group is substituted with at least one trifluoromethyl group.
21. The compound according to claim 20, wherein said optionally substituted phenyl group is substituted with at least two trifluoromethyl groups
22. The compound according to claim 19, wherein said optionally substituted phenyl group is substituted with at least one lower alkyl group.
23. The compound according to claim 19, wherein R3b is -H.
24. The compound according to claim 23, wherein R4b is selected from R3, -H, -CO2R3, -C(O)N(R3)R4, and -C(O)R3.
25. The compound according to claim 24, wherein Ar is according to the formula below.
26. The compound according to claim 24, wherein Ar is according to the formula below.
27. The compound according to claim 24, wherein Ar is according to the formula below.
28. The compound according to claim 24, wherein Ar is according to the formula below.
29. The compound according to claim 24, wherein Ar is according to the formula below.
30. A compound for modulating kinase activity of Formula IV, or a pharmaceutically acceptable salt, hydrate, or prodrug thereof, wherein, Ar is selected from the following formulae:
each R1 is independently selected from -H, halogen, -CN, -NO2, -OR3, -N(R3)R3, -S(O)0-2R3, -SO2N(R3)R3, -CO2R3, -C(O)N(R3)R3, -N(R3)SO2R3, -N(R3)C(O)R3, -N(R3)CO2R3, -C(O)R3, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl;
optionally two of R1, together with the atoms to which they are attached, form a first ring system fused with Ar, said first ring system substituted with zero to three additional of R1;
each R2 is independently selected from -H, halogen, oxo, -CN, -NH2, -NO2, -OR3, -N(R3)R3, -N(R3)R5, -S(O)0-2R3, -SO2N(R3)R3, -CO2R3, -C(O)N(R3)R3, -N(R3)SO2R3, -N(R3)C(O)R3, -N(R3)CO2R3, -N(R3)C(O)N(R3)R3, -C(O)R3, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl;
two of R2, together with the atoms to which they are attached, can form an optionally substituted three- to seven-membered ring system;
each R3 is independently selected from -H, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; or two of R3, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl ring, said optionally substituted five- to seven-membered heterocyclyl ring optionally containing at least one additional heteroatom selected from N, O, S, and P;
each R4 is independently selected from R3, -SO2R3, -S02N(R3)R3, -CO2R3, -C(O)N(R3)R3, and -C(O)R3;
Y is selected from optionally substituted -CH2-, -O-, -S-, and -N(R3)-;
L is selected from optionally substituted -CH2-, -O-, -S-, -N(R3)- and absent;
provided that Y and L are not both heteroatoms;
B is =N- or =C(H)-;
at each instance, R5 and R6 are independently selected from -H, halogen, -CN, -NO2, -OR3, -N(R3)R4, -S(O)0-2R3, -SO2N(R3)R3, -CO2R3, -C(O)N(R3)R, -N(R3)SO2R3, -N(R3)C(O)R3, -N(R3)CO2R3, -C(O)R3, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; and optionally two of R5, together with the atoms to which they are attached, form a ring system fused with the ring containing B according to formula IV, said ring system substituted with zero to two additional of R5.
each R1 is independently selected from -H, halogen, -CN, -NO2, -OR3, -N(R3)R3, -S(O)0-2R3, -SO2N(R3)R3, -CO2R3, -C(O)N(R3)R3, -N(R3)SO2R3, -N(R3)C(O)R3, -N(R3)CO2R3, -C(O)R3, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl;
optionally two of R1, together with the atoms to which they are attached, form a first ring system fused with Ar, said first ring system substituted with zero to three additional of R1;
each R2 is independently selected from -H, halogen, oxo, -CN, -NH2, -NO2, -OR3, -N(R3)R3, -N(R3)R5, -S(O)0-2R3, -SO2N(R3)R3, -CO2R3, -C(O)N(R3)R3, -N(R3)SO2R3, -N(R3)C(O)R3, -N(R3)CO2R3, -N(R3)C(O)N(R3)R3, -C(O)R3, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl;
two of R2, together with the atoms to which they are attached, can form an optionally substituted three- to seven-membered ring system;
each R3 is independently selected from -H, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; or two of R3, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl ring, said optionally substituted five- to seven-membered heterocyclyl ring optionally containing at least one additional heteroatom selected from N, O, S, and P;
each R4 is independently selected from R3, -SO2R3, -S02N(R3)R3, -CO2R3, -C(O)N(R3)R3, and -C(O)R3;
Y is selected from optionally substituted -CH2-, -O-, -S-, and -N(R3)-;
L is selected from optionally substituted -CH2-, -O-, -S-, -N(R3)- and absent;
provided that Y and L are not both heteroatoms;
B is =N- or =C(H)-;
at each instance, R5 and R6 are independently selected from -H, halogen, -CN, -NO2, -OR3, -N(R3)R4, -S(O)0-2R3, -SO2N(R3)R3, -CO2R3, -C(O)N(R3)R, -N(R3)SO2R3, -N(R3)C(O)R3, -N(R3)CO2R3, -C(O)R3, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; and optionally two of R5, together with the atoms to which they are attached, form a ring system fused with the ring containing B according to formula IV, said ring system substituted with zero to two additional of R5.
31. The compound according to claim 30, wherein Y is -O- and L is optionally substituted -CH2-.
32. The compound according to claim 31, wherein at least one of R6 is optionally substituted lower alkyl.
33. The compound according to claim 32, wherein said at least one optionally substituted lower alkyl is meta- to the piperazine urea function as depicted in formula IV.
34. The compound according to claim 33, wherein R4a is selected from R3, -H, -CO2R3, -C(O)N(R3)R4, and -C(O)R3.
35. The compound according to claim 34, wherein R4a is selected from -H, -CO2R3, -C(O)N(R3)R4, and -C(O)R3.
36. The compound according to claim 35, wherein -Y-L- is -OCH2-.
37. The compound according to claim 36, wherein Ar is according to the formula below.
38. The compound according to claim 36, wherein Ar is according to the formula below.
39. The compound according to claim 36, wherein Ar is according to the formula below.
40. The compound according to claim 36, wherein Ar is according to the formula below.
41. The compound according to claim 36, wherein Ar is according to the formula below.
42. The compound according to claim 1, selected from Table 4.
19~
19~
43. A pharmaceutical composition comprising the compound according to any one of claims 1 - 42 and a pharmaceutically acceptable carrier.
44. A metabolite of the compound or the pharmaceutical composition according to any one of claims 1 - 43.
45. A method of modulating the in vivo activity of a kinase, the method comprising administering to a subject an effective amount of a composition comprising at least one of the compound according to any of claims 1 - 42 and the pharmaceutical composition according to claim 43.
46. The method according to claim 45, wherein the kinase is Tie-2.
47. The method according to claim 46, wherein modulating the in vivo activity of Tie-2 comprises inhibition of Tie-2.
48. A method of treating diseases or disorders associated with uncontrolled, abnormal, and/or unwanted cellular activities, the method comprising administering, to a mammal in need thereof, a therapeutically effective amount of a composition comprising at least one of the compound according to any of claims 1 - 42 and the pharmaceutical composition according to claim 43.
49. A method of screening for modulator of a Tie-2 kinase, the method comprising combining either a composition comprising at least one of the compound according to any of claims 1 - 42 and the pharmaceutical composition according to claim 43, and at least one candidate agent and determining the effect of the candidate agent on the activity of said kinase.
50. A method of inhibiting proliferative activity in a cell, the method comprising administering to said cell an effective amount of at least one of the compound according to any of claims 1 - 42 and the pharmaceutical composition according to claim 43.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45656503P | 2003-03-19 | 2003-03-19 | |
| US60/456,565 | 2003-03-19 | ||
| PCT/US2004/008579 WO2004083235A2 (en) | 2003-03-19 | 2004-03-19 | Tie-2 modulators and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2517291A1 true CA2517291A1 (en) | 2004-09-30 |
| CA2517291C CA2517291C (en) | 2012-05-08 |
Family
ID=33030100
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2517291A Expired - Fee Related CA2517291C (en) | 2003-03-19 | 2004-03-19 | Ortho-substituted aryl and heteroaryl tie-2 modulators and methods of use |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8013156B2 (en) |
| EP (1) | EP1608373A4 (en) |
| JP (1) | JP4960085B2 (en) |
| AU (1) | AU2004221812B2 (en) |
| CA (1) | CA2517291C (en) |
| WO (1) | WO2004083235A2 (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050124625A1 (en) * | 2003-10-21 | 2005-06-09 | Salvati Mark E. | Piperazine derivatives and their use as modulators of nuclear hormone receptor function |
| CA2587642C (en) | 2004-11-30 | 2013-04-09 | Amgen Inc. | Substituted heterocycles and methods of use |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Substituted Amid derivatives & methods of use |
| AU2013211455B2 (en) * | 2005-09-19 | 2017-12-07 | Neuronascent, Inc. | Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration |
| KR101158568B1 (en) | 2005-09-19 | 2012-07-02 | 뉴로내슨트, 아이엔씨. | Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration |
| EP2076499B1 (en) * | 2006-10-04 | 2010-05-12 | F.Hoffmann-La Roche Ag | Pyrazine-2-carboxamide derivatives as cb2 receptor modulators |
| EP2307456B1 (en) | 2008-06-27 | 2014-10-15 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
| GB0818241D0 (en) | 2008-10-06 | 2008-11-12 | Cancer Res Technology | Compounds and their use |
| EP2387563B2 (en) | 2009-01-16 | 2022-04-27 | Exelixis, Inc. | Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quinolin-4-yl]oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
| UY33198A (en) * | 2010-01-26 | 2011-08-31 | Boehringer Ingelheim Int | 5-ALQUINIL-PYRIMIDINS. |
| WO2012061337A1 (en) | 2010-11-02 | 2012-05-10 | Exelixis, Inc. | Fgfr2 modulators |
| CN105636945B (en) | 2013-10-14 | 2017-11-17 | 卫材R&D管理有限公司 | The quinoline compound selectively substituted |
| SI3057964T1 (en) | 2013-10-14 | 2020-03-31 | Eisai R&D Management Co., Ltd. | Selectively substituted quinoline compounds |
| TWI704145B (en) | 2015-06-05 | 2020-09-11 | 芬蘭商奧利安公司 | New pharmaceutical compounds |
| WO2024035627A1 (en) * | 2022-08-08 | 2024-02-15 | Ajax Therapeutics, Inc. | Heterocyclic amide and urea compounds as jak2 inhibitors |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI193974A (en) * | 1973-07-13 | 1975-01-14 | Merck & Co Inc | |
| DE2428030A1 (en) | 1974-06-11 | 1976-01-02 | Merck Sharp & Dohme | 4-(3-Amino-2-acyloxypropoxyl)-1,2,5-thiadiazoles - useful as beta-adrenergic blocking agents |
| EP0096006A3 (en) | 1982-05-28 | 1984-12-19 | Ciba-Geigy Ag | 3-(ureidocyclohexylamino)-propane-1,2-diol derivatives, process for their preparation, pharmaceutical preparations containing these compounds and their therapeutical use |
| US4547505A (en) * | 1983-03-25 | 1985-10-15 | Degussa Aktiengesellschaft | N-Phenyl-N-'-cycloalkylalkanoylpiperazine useful as analgetics and process for its production |
| US4994476A (en) | 1984-10-31 | 1991-02-19 | Bristol-Myers Company | Dihydropyridin-3,5-dicarboxylates incorporating aryloxypropanolamine moieties |
| IT1191845B (en) | 1986-01-20 | 1988-03-23 | Dompe Farmaceutici Spa | PHARMACOLOGICALLY ACTIVE ALCHYLOLS |
| US4954502A (en) | 1988-06-10 | 1990-09-04 | Bristol-Myers Squibb Company | 1-indolyalkyl-4-(substituted-pyridinyl)piperazines |
| SE8803429D0 (en) | 1988-09-28 | 1988-09-28 | Pharmacia Ab | NOVEL PYRIDYL AND PYRIMIDYL DERIVATIVES |
| DE4134467A1 (en) * | 1991-10-18 | 1993-04-22 | Thomae Gmbh Dr K | HETEROBIARYL DERIVATIVES, MEDICAMENTS CONTAINING THESE COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF |
| SE9202265D0 (en) | 1992-07-31 | 1992-07-31 | Kabi Pharmacia Ab | NOVEL- PYRIDYL AND PYRIMIDYLPIPERAZINE DERIVATIVES |
| TW279864B (en) * | 1993-02-19 | 1996-07-01 | Janssen Pharmaceutica Nv | |
| US5639754A (en) * | 1994-07-12 | 1997-06-17 | Janssen Pharmaceutica N.V. | Urea and thiourea derivatives of azolones |
| US5637592A (en) * | 1994-07-12 | 1997-06-10 | Janssen Pharmaceutica N.V. | Acyl derivatives of azolones |
| US5571811A (en) * | 1994-07-12 | 1996-11-05 | Janssen Pharmaceutica N.V. | Sulfonamide derivatives of azolones |
| CA2184919C (en) * | 1995-01-11 | 2000-03-14 | Eui-Hwan Cho | New piperazine derivatives and methods for the preparation thereof and compositions containing the same |
| DE69716916T2 (en) * | 1996-07-13 | 2003-07-03 | Glaxo Group Ltd | CONDENSED HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS |
| GB9713087D0 (en) | 1997-06-20 | 1997-08-27 | Celltech Therapeutics Ltd | Chemical compounds |
| JPH1180119A (en) | 1997-07-15 | 1999-03-26 | Sankyo Co Ltd | Piperazine derivative |
| US6462036B1 (en) | 1998-11-06 | 2002-10-08 | Basf Aktiengesellschaft | Tricyclic pyrazole derivatives |
| PT1161424E (en) | 1999-03-03 | 2004-08-31 | Wyeth Corp | NEW DIAZOLE DERIVATIVES AS SEROTONERGIC AGENTS |
| EA005820B1 (en) | 1999-05-21 | 2005-06-30 | Биовитрум Аб | Agonists and antagonists of 5-ht2c receptors |
| SE9901884D0 (en) * | 1999-05-21 | 1999-05-21 | Pharmacia & Upjohn Ab | Novel compounds their use and preparation |
| US6921763B2 (en) * | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| EP1088821A1 (en) * | 1999-09-28 | 2001-04-04 | Applied Research Systems ARS Holding N.V. | Pharmaceutically active sulfonamide derivatives |
| EP1301484A2 (en) * | 2000-07-20 | 2003-04-16 | Neurogen Corporation | Capsaicin receptor ligands |
| US7186715B2 (en) * | 2001-01-08 | 2007-03-06 | Eli Lilly And Company | Piperazine- and piperidine-derivatives as melanocortin receptor agonists |
| CA2436487A1 (en) | 2001-01-30 | 2002-08-08 | Cytopia Pty Ltd. | Methods of inhibiting kinases |
| JP2005511478A (en) * | 2001-04-03 | 2005-04-28 | メルク エンド カムパニー インコーポレーテッド | N-substituted non-aryl heterocyclic amidyl NMDA / NR2B antagonist |
| US7064215B2 (en) | 2001-07-03 | 2006-06-20 | Chiron Corporation | Indazole benzimidazole compounds |
| AU2003236500B9 (en) * | 2002-06-12 | 2009-07-02 | Chemocentryx, Inc. | 1-aryl-4-substituted piperazine derivatives for use as CCR1 antagonists for the treatment of inflammation and immune disorders |
| US7320979B2 (en) * | 2003-04-14 | 2008-01-22 | Abbott Gmbh & Co. Kg. | N-[(piperazinyl)hetaryl]arylsulfonamide compounds |
-
2004
- 2004-03-19 WO PCT/US2004/008579 patent/WO2004083235A2/en active Application Filing
- 2004-03-19 JP JP2006507414A patent/JP4960085B2/en not_active Expired - Fee Related
- 2004-03-19 AU AU2004221812A patent/AU2004221812B2/en not_active Ceased
- 2004-03-19 CA CA2517291A patent/CA2517291C/en not_active Expired - Fee Related
- 2004-03-19 US US10/549,300 patent/US8013156B2/en not_active Expired - Fee Related
- 2004-03-19 EP EP04757665A patent/EP1608373A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US8013156B2 (en) | 2011-09-06 |
| AU2004221812B2 (en) | 2010-02-18 |
| US20070275952A1 (en) | 2007-11-29 |
| EP1608373A4 (en) | 2010-09-29 |
| WO2004083235A2 (en) | 2004-09-30 |
| WO2004083235A3 (en) | 2005-03-03 |
| AU2004221812A1 (en) | 2004-09-30 |
| JP4960085B2 (en) | 2012-06-27 |
| JP2006524682A (en) | 2006-11-02 |
| EP1608373A2 (en) | 2005-12-28 |
| CA2517291C (en) | 2012-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2517291A1 (en) | Ortho-substituted aryl and heteroaryl tie-2 modulators and methods of use | |
| IL278297B1 (en) | Substituted heterocyclic inhibitors of ptpn11 | |
| CA2536954A1 (en) | C-kit modulators and methods of use | |
| RU2348617C2 (en) | 2-pyridone derivatives as inhibitors of neutrophil elastase, and their application | |
| CA2620534C (en) | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | |
| EP2887943B1 (en) | Novel 4,6-disubstituted aminopyrimidine derivatives | |
| CA2564990A1 (en) | Morpholine compounds | |
| CN104876912A (en) | Wnt signal channel inhibitor and application thereof | |
| AR073548A1 (en) | COMPOUNDS DERIVED FROM DIAZOL AND TRIAZOL, COMPOSITIONS AND USE OF THE SAME TO MODULATE URIC ACID LEVELS | |
| DE69829875D1 (en) | PIPERAZINE COMPOUNDS AND ITS MEDICAL USE | |
| HU9700030D0 (en) | 2-(1',2',4'-triazol-3'-yloxymethylene)-anilides and their use as pestcontrol agents | |
| DE69835430D1 (en) | Sulphonamide derivatives, their preparation and their use | |
| FI963238A0 (en) | Heteroaromatic oxazole compounds and their use | |
| EA201070018A1 (en) | SUBSTITUTED 2- [2- (PHENYL) ETHYLAMINO] ALKANAMIDE DERIVATIVES AND APPLICATION OF THE SPECIFIED COMPOUNDS AS MODULATORS OF SODIUM AND / OR CALCIUM CHANNELS | |
| JP7025359B2 (en) | Heteroaryl compounds that are necrosis inhibitors, their compositions and uses | |
| KR20200055034A (en) | Cyclic iminopyrimidine derivatives as kinase inhibitors | |
| DE3681359D1 (en) | 6-PHENYL-PYRIDAZINE COMPOUNDS. | |
| JP2006524682A5 (en) | ||
| CA2501335A1 (en) | Compounds capable of activating cholinergic receptors | |
| TW200626571A (en) | Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | |
| ES509219A0 (en) | "A PROCEDURE FOR THE PREPARATION OF 5-HALOPYRIMIDIN-2-ONAS". | |
| ES2821962T3 (en) | Sodium channel blocker | |
| US20070213378A1 (en) | Compounds for modulating cell proliferation, compositions and methods related thereto | |
| CA2439480A1 (en) | Carbamate compounds for use in preventing or treating psychotic disorders | |
| JP2014530813A (en) | Phenyl-guanidine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20160321 |